Company intelligence / Profile preview
G+FLAS Life Sciences
Seoul, Gyeonggi-do, South Koreagflas.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Developing plant-based trastuzumab biosimilar (GF003) with improved ADCC via glycotechnology; pro-vitamin D3 tomatoes via non-GMO CRISPR editing; no reported clinical trial results.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyGene therapyCRISPR-based therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
BayerERS GenomicsKangStem BiotechChungbuk National University
Beyond the preview
Go deeper on G+FLAS Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G+FLAS Life Sciences.